+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07868861

Comparing Ondansetron Nasal Spray and IV Infusion Bioavailability in Healthy Adults Aged 18 to 65

Led by Nasus Pharma · Updated on 2026-10-09

12

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the bioavailability of ondansetron, a drug used to treat nausea and vomiting, when given via nasal spray NS003 compared to intravenous IV administration in healthy adults aged 18 to 65 years. This Phase 1, non-randomized, crossover study aims to understand how much ondansetron enters the bloodstream and how it behaves over 24 hours after dosing through two different methods. Participants will receive ondansetron in three different forms a nasal microsphere powder at 5 mg and 10 mg doses using a nasal device, and a marketed 8 mg IV infusion solution. Each participant will receive these treatments in a crossover manner to compare the drugs absorption and concentration in the blood over time following dosing. During the study, participants will stay in the clinic for the entire confinement period to allow detailed blood sampling and monitoring. Researchers will measure plasma ondansetron levels from dosing up to 24 hours, including peak concentration, time to peak, and drug elimination rates. Safety will be closely monitored through adverse event tracking, physical exams, vital signs, ECGs, and laboratory tests, with follow-up continuing one week after the last dose.

CONDITIONS

Brief Title

A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here